Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 3/20 | 0.53 |
| ▸ | TLR2 | O60603 | 2/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10020438 | 1.00 | MDM4 (0.54) | MDM4TP53SLC17A5CASP3TLR2 | |
| SCHEMBL31197005 | 0.94 | MDM4 (0.54) | MDM4TP53SLC17A5CASP3TLR2 | |
| SCHEMBL13253077 | 0.92 | CASP3 (0.48) | MDM4TP53SLC17A5CASP3MDM2 | |
| SCHEMBL29540266 | 0.92 | PTPN1 (0.48) | MDM4TP53SLC17A5CASP3 | |
| SCHEMBL16288088 | 0.92 | PTPN1 (0.48) | MDM4TP53SLC17A5CASP3 | |
| SCHEMBL27222134 | 0.92 | PTPN1 (0.48) | MDM4TP53SLC17A5CASP3 | |
| SCHEMBL6517147 | 0.90 | CASP3 (0.47) | MDM4TP53SLC17A5CASP3 | |
| SCHEMBL27008576 | 0.90 | MDM4 (0.49) | MDM4TP53SLC17A5CASP3MDM2 | |
| SCHEMBL27129147 | 0.90 | MDM4 (0.49) | MDM4TP53SLC17A5CASP3MDM2 | |
| SCHEMBL7592482 | 0.90 | MDM4 (0.46) | MDM4TP53SLC17A5CASP3TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118490852-A | Intracellular-constructed legumain-responded PET/MR bimodal molecular probe and application thereof | 安徽医科大学第一附属医院 | 2024-08-16 | — | — | CN | claimed |
| CN-114957388-B | Short peptide fluorescent probe and preparation method and application thereof | 国家纳米科学中心 | 2024-04-30 | — | — | CN | claimed |
| CN-115010786-B | GSH-hypoxia microenvironment double-response self-assembled fluorescent probe and preparation method and application thereof | 国家纳米科学中心 | 2024-03-12 | — | — | CN | claimed |
| CN-115010786-A | GSH-hypoxic microenvironment dual-response self-assembly fluorescent probe and preparation method and application thereof | 国家纳米科学中心 | 2022-09-06 | — | — | CN | claimed |
| CN-114957388-A | Short peptide fluorescent probe and preparation method and application thereof | 国家纳米科学中心 | 2022-08-30 | — | — | CN | claimed |
| CN-114616236-A | Process for preparing cysteic acid-containing polypeptides | 江苏金斯瑞生物科技有限公司 | 2022-06-10 | — | — | CN | claimed |
| CN-113956333-B | Synthesis and purification method of linaclotide | 浙江湃肽生物有限公司南京分公司 | 2022-03-29 | — | — | CN | claimed |
| CN-114867527-B | Macrocyclic peptides | Herantis pharmaceutical Co. (FI) | 2026-05-26 | — | — | CN | disclosed |
| CN-122011071-A | Synthesis method and application of DNA-ketoamide conjugate | 重庆大学 | 2026-05-12 | — | — | CN | disclosed |
| US-20250353875-A1 | PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-11-20 | — | — | US | disclosed |
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| EP-4611793-A1 | INSULIN DERIVATIVES | Ustav organicke chemie a biochemie Akademie ved CR, v.v.i. (CZ) | 2025-09-10 | — | — | EP | disclosed |
| US-20250243290-A1 | AGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR 2 ANTIBODIES | THE GENERAL HOSPITAL CORPORATION | 2025-07-31 | — | — | US | disclosed |
| EP-0833648-A4 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | JOLLA PHARMA (US) | 1999-10-13 | — | — | EP | disclosed |
| EP-0954531-A4 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | LAJOLLA PHARMACEUTICAL COMPANY (US) | 1999-08-31 | — | — | EP | disclosed |
| WO-1997046251-A9 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | — | 1998-06-04 | — | — | WO | disclosed |
| EP-0833648-A1 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | LA JOLLA PHARMACEUTICAL (US) | 1998-04-08 | — | — | EP | disclosed |
| WO-1997046251-A1 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | LAJOLLA PHARMACEUTICAL COMPANY (US) | 1997-12-11 | — | — | WO | disclosed |
| WO-1996040197-A9 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | — | 1997-04-24 | — | — | WO | disclosed |
| WO-1996040197-A1 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | LA JOLLA PHARMACEUTICAL COMPANY (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353875-A1 | PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION | VIP, NPPA, DNPEP | MDM4 3469/4885TP53 3832/4885SLC17A5 3772/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | MDM4 3559/4885TP53 2654/4885SLC17A5 2582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.